Merck Stock Quote Today

MRK
 Stock
  

USD 110.01  0.03  0.0273%   

Market Performance
22 of 100
Odds Of Distress
Less than 7
Merck is trading at 110.01 as of the 5th of December 2022. This is a -0.03 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 109.21. Merck has only a 7 % chance of going through financial distress over the next few years and had a solid performance during the last 90 days. Equity ratings for Merck Company are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 13th of July 2021 and ending today, the 5th of December 2022. Click here to learn more.
CUSIP
589339209
Fiscal Year End
December
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
13th of January 1978
Category
Healthcare
Classification
Health Care
Merck Co., Inc. operates as a healthcare company worldwide. Merck Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey. Merck operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. The company has 2.54 B outstanding shares of which 19.47 M shares are now shorted by investors with about 1.95 days to cover. More on Merck Company

Moving against Merck

-0.76EDITEditas Medicine Normal TradingPairCorr
-0.76IRTCIRhythm Technologies Downward RallyPairCorr
-0.65BEAMBeam TherapeuticsInc Normal TradingPairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Merck Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Merck's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Merck or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Over 76.0% of the company shares are owned by institutional investors
Latest headline from news.google.com: Is Merck Co. Outperforming Other Medical Stocks This Year - Nasdaq
ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary, Merck's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Merck's managers, analysts, and investors.
Environment Score
Governance Score
Social Score
ChairmanKenneth Frazier
Thematic Ideas
Showing 3 out of 4 themes
Excise Tax ActivitiesAnimal TestingCatholic
Fama & French Classification
Average Analyst Recommendation
Analysts covering Merck report their recommendations after researching Merck's financial statements, talking to executives and customers, or listening in on Merck's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Merck Company. The Merck consensus assessment is calculated by taking the average forecast from all of the analysts covering Merck.
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Merck Company based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Merck Company financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
HealthyDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares DilutedB2.5 B
Fairly Up
Decreasing
Slightly volatile
Weighted Average Shares3.2 B2.9 B
Significantly Up
Decreasing
Slightly volatile
Return on Average Assets14.2713.2288
Significantly Up
Increasing
Slightly volatile
Net Cash Flow from Operations11.5 B13.1 B
Fairly Down
Increasing
Stable
Current Liabilities20.9 B23.9 B
Fairly Down
Increasing
Slightly volatile
Total Liabilities59.2 B67.5 B
Fairly Down
Increasing
Slightly volatile
Gross Margin65.4572.0228
Moderately Down
Increasing
Slightly volatile
Total Debt32 B33.1 B
Sufficiently Down
Increasing
Slightly volatile
Asset Turnover0.450.4938
Significantly Down
Increasing
Slightly volatile
Current Assets33.4 B30.3 B
Significantly Up
Decreasing
Slightly volatile
Total Assets112.1 B105.7 B
Notably Up
Decreasing
Stable
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Merck's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong BuyFairly Valued
Financial Strength
Merck's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Merck's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Merck's bond ratings measure its overall creditworthiness, which in many ways corresponds to the cost of borrowing for an issuer. These ratings assign a letter grade to all of Merck's outstanding corporate bonds that indicate their credit quality. We use reports published by private self-sufficient rating services such as Standard & Poor's or Fitch Ratings Inc. to evaluate a bond issuer's financial strength or its ability to pay a bond's principal and interest.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Merck's financial leverage. It provides some insight into what part of Merck's total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Merck's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Merck deploys its capital and how much of that capital is borrowed.
Liquidity
Merck cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company has 30.69 B in debt with debt to equity (D/E) ratio of 0.68, which is OK given its current industry classification. Merck Company has a current ratio of 1.43, which is typical for the industry and considered as normal. Debt can assist Merck until it has trouble settling it off, either with new capital or with free cash flow. So, Merck's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Merck Company sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Merck to invest in growth at high rates of return. When we think about Merck's use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

11.46 Billion
Merck Company (MRK) is traded on New York Stock Exchange in USA and employs 67,000 people. Merck is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mega-Cap' category with total capitalization of 279.61 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Merck's market, we take the total number of its shares issued and multiply it by Merck's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Merck Company runs under Pharmaceuticals sector within Health Care industry. The entity has 2.54 B outstanding shares of which 19.47 M shares are now shorted by investors with about 1.95 days to cover. Merck Company has about 8.1 B in cash with 14.11 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.44.
Check Merck Probability Of Bankruptcy
Ownership
Merck Company maintains a total of two billion five hundred thirty-five million three hundred ninety-nine thousand nine hundred thirty-six outstanding shares. The majority of Merck outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Merck Company to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Merck Company. Please pay attention to any change in the institutional holdings of Merck as this could imply that something significant has changed or about to change at the company. Please note that no matter how much assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Ownership Allocation (%)

Check Merck Ownership Details

Merck Stock Price Odds Analysis

Coming from a normal probability distribution, the odds of Merck jumping above the current price in 90 days from now is roughly 2.68%. The Merck Company probability density function shows the probability of Merck stock to fall within a particular range of prices over 90 days. Considering the 90-day investment horizon Merck has a beta of 0.3106. This indicates as returns on the market go up, Merck average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Merck Company will be expected to be much smaller as well. Additionally, the company has an alpha of 0.3662, implying that it can generate a 0.37 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
  Odds Below 110.01HorizonTargetOdds Above 110.01
97.29%90 days
 110.01 
2.68%
Based on a normal probability distribution, the odds of Merck to move above the current price in 90 days from now is roughly 2.68 (This Merck Company probability density function shows the probability of Merck Stock to fall within a particular range of prices over 90 days) .

Merck Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Merck that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Merck's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Merck's value.
InstituionSecurity TypeTotal SharesValue
Zwj Investment Counsel IncCommon Shares294.9 K25.4 M
Zwj Investment Counsel IncCommon Shares323.7 K29.5 M
View Merck Diagnostics

Merck Historical Income Statement

Merck Company Income Statement is one of the three primary financial statements used for reporting Merck's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Merck Company revenue and expense. Merck Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Merck Operating Income is increasing as compared to previous years. The last year's value of Operating Income was reported at 12.54 Billion. The current Weighted Average Shares is estimated to increase to about 3.2 B, while Earning Before Interest and Taxes EBIT is projected to decrease to under 12.8 B. View More Fundamentals

Be your own money manager

Our tools can tell you how much better you can do entering a position in Merck without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Commodity Channel Index Now

   

Commodity Channel Index

Use Commodity Channel Index to analyze current equity momentum
All  Next Launch Module

Merck Corporate Directors

Merck corporate directors refer to members of a Merck board of directors. The board of directors generally takes responsibility for the Merck's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Merck's board members must vote for the resolution. The Merck board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Rochelle Lazarus - Independent DirectorProfile
Paul Rothman - Independent DirectorProfile
Mary Coe - Independent DirectorProfile
Patricia Russo - Independent DirectorProfile

Invested in Merck Company?

The danger of trading Merck Company is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Merck is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Merck. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Merck Company is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additionally, see Correlation Analysis. You can also try Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

Complementary Tools for analysis

When running Merck Company price analysis, check to measure Merck's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merck is operating at the current time. Most of Merck's value examination focuses on studying past and present price action to predict the probability of Merck's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Merck's price. Additionally, you may evaluate how the addition of Merck to your portfolios can decrease your overall portfolio volatility.
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Is Merck's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Merck. If investors know Merck will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Merck listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
(0.29) 
Market Capitalization
279.6 B
Quarterly Revenue Growth YOY
0.14
Return On Assets
0.13
Return On Equity
0.38
The market value of Merck Company is measured differently than its book value, which is the value of Merck that is recorded on the company's balance sheet. Investors also form their own opinion of Merck's value that differs from its market value or its book value, called intrinsic value, which is Merck's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Merck's market value can be influenced by many factors that don't directly affect Merck's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Merck's value and its price as these two are different measures arrived at by different means. Investors typically determine Merck value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merck's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.